Literature DB >> 12866375

Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations.

Zhaowen Zhu1, Manoj Gandhi, Marina N Nikiforova, Andrew H Fischer, Yuri E Nikiforov.   

Abstract

The follicular variant (FV) of papillary thyroid carcinoma is characterized by a follicular growth pattern and cytologic features of papillary carcinoma. ret/PTC rearrangements are common in classic papillary thyroid carcinoma (PTC) and PAX8-PPAR gamma and ras mutations in follicular thyroid carcinoma. Their prevalence in FV has not been established. We studied these genetic alterations and clinical-pathologic features in 30 FV cases and compared those with 46 non-FV papillary carcinomas. FV cases revealed 1 ret/PTC rearrangement (3%) and 13 ras mutations (43%). Non-FV cases harbored 13 ret/PTC (28%) (P = .006) and no ras mutations (P = .0002). No PAX8-PPAR gamma was found in either group. FV cases demonstrated a significantly higher prevalence of tumor encapsulation, angiovascular invasion, and poorly differentiated areas and a lower rate of lymph node metastases. These data indicate that the FV of papillary carcinoma has a distinct set of molecular alterations and is characterized by a high frequency of ras point mutations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12866375     DOI: 10.1309/ND8D-9LAJ-TRCT-G6QD

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  110 in total

1.  Cytological detection of papillary thyroid carcinomas by nuclear membrane decoration with emerin staining.

Authors:  Sofia Asioli; Francesca Maletta; Donatella Pacchioni; Rosanna Lupo; Gianni Bussolati
Journal:  Virchows Arch       Date:  2010-05-26       Impact factor: 4.064

2.  Invasion rather than nuclear features correlates with outcome in encapsulated follicular tumors: further evidence for the reclassification of the encapsulated papillary thyroid carcinoma follicular variant.

Authors:  Ian Ganly; Laura Wang; R Michael Tuttle; Nora Katabi; Gustavo A Ceballos; H Ruben Harach; Ronald Ghossein
Journal:  Hum Pathol       Date:  2015-02-04       Impact factor: 3.466

3.  The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells.

Authors:  Rosa Marina Melillo; Maria Domenica Castellone; Valentina Guarino; Valentina De Falco; Anna Maria Cirafici; Giuliana Salvatore; Fiorina Caiazzo; Fulvio Basolo; Riccardo Giannini; Mogens Kruhoffer; Torben Orntoft; Alfredo Fusco; Massimo Santoro
Journal:  J Clin Invest       Date:  2005-03-10       Impact factor: 14.808

Review 4.  Our approach to follicular-patterned lesions of the thyroid.

Authors:  Zubair W Baloch; Virginia A LiVolsi
Journal:  J Clin Pathol       Date:  2006-06-23       Impact factor: 3.411

Review 5.  Diagnostic criteria in well-differentiated thyroid carcinomas.

Authors:  Elsa Fonseca; Paula Soares; Manuel Cardoso-Oliveira; Manuel Sobrinho-Simões
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

6.  Microarray analysis of thyroid nodule fine-needle aspirates accurately classifies benign and malignant lesions.

Authors:  Carrie C Lubitz; Stacy K Ugras; J Jacob Kazam; Biaxin Zhu; Theresa Scognamiglio; Yao-Tseng Chen; Thomas J Fahey
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

Review 7.  Understanding the genotype of follicular thyroid tumors.

Authors:  Jennifer Hunt
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

8.  Identification of a novel HRAS variant and its association with papillary thyroid carcinoma.

Authors:  Rui Dou; Lili Zhang; Tingxia Lu; Dong Liu; Fang Mei; Jian Huang; Linxue Qian
Journal:  Oncol Lett       Date:  2018-01-17       Impact factor: 2.967

Review 9.  Molecular pathogenesis and mechanisms of thyroid cancer.

Authors:  Mingzhao Xing
Journal:  Nat Rev Cancer       Date:  2013-03       Impact factor: 60.716

10.  BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.

Authors:  Rebecca Leboeuf; Jacqueline E Baumgartner; Miriam Benezra; Roberta Malaguarnera; David Solit; Christine A Pratilas; Neal Rosen; Jeffrey A Knauf; James A Fagin
Journal:  J Clin Endocrinol Metab       Date:  2008-04-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.